Ibars BE, Borroto DG, Guerrero DC, Barceló AM

Language: Spanish
References: 20
Page: 3-14
PDF size: 162.22 Kb.

ABSTRACT

Introduction: The insulin-resistance syndrome (IRS) is a frequent complication in the renal transplantation due to multiple factors.
Objective: To know which alterations linked to renal transplantation and its treatment are risk factors for appearance of insulin-resistance syndrome.
Methods: A case-control study was conducted in 81 patients underwent renal transplantation, with a graft survival higher than 1 year and not to be diabetics before implant. Two groups were established, one including patients with this syndrome (n= 39) according to the ATP-III criteria and another as control (n= 42). To detect the risk factors pre-transplantation the following variables were compared: age or receptor, time in dialysis, glycemia figures, cholesterol and triglycerides, body mass index (BMI), infection for hepatitis C and a family history of diabetes and post-transplantation variables included immunosuppressive treatment, dose of steroids at third month post-transplantation, cyclosporine A levels and presence or not of rejection. The pre-transplantation variables were categorized in a suitable way for univariate and multivariate analysis where they were statistically significant, in the univariate study: the largest time in dialysis, the great age of recipient, the high figures of pre-transplantation glycemia, the positive to Virus C, body mass index higher than 25 and family history of diabetes, this latter factor was the only with statistic representativeness in multivariate analysis. Analyzing the variables linked to immunosuppressive treatment, only we note that patients with this syndrome had statistically mean values of cyclosporine higher than those without this complication.
Conclusions: The insulin resistance syndrome is developed from the alterations present before transplantation and at the moment of implant with the addition of other during the implant course, mainly the immunosuppressive treatment.

REFERENCES

1. Kishikawa H, Nishimura K, Kato T, Kobayashi Y, Arichi N, Okuno A, et al. Prevalence of the metabolic syndrome in kidney transplantation. Transplant Proc. 2009;41(1):181-3.

2. Sui W, Zou H, Zou G, Yan Q, Chen H, Che W, et al. Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. Transpl Immunol. 2008;20(1-2):95-8.

3. Young DO, Lund RJ, Haynatzki G, Dunlay RW. Prevalence of the metabolic syndrome in an incident dialysis population. Hemodial Int. 2007;11(1):86-95.

4. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM.Results of an International Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. Am J Transplant. 2007;42(4):123-7.

5. Lo A. Immunosuppression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord. 2004;2(4):263-73.

6. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285(19):2486-96.

7. American Diabetes Association. Diagnosis and clasification of diabetes mellitus. Diabetes Care. 2004;27(S 1):S5-S10.

8. Silva LC. Excursión a la regresión logística en ciencias de la salud. Madrid: Díaz de Santos; 1993.

9. Dawson-Saunders B, Trapp RG. Bioestadística Médica. México: El Manual Moderno; 1999. p. 249-72.

10. Borroto G, Batista F, Barceló M, Guerrero C. Frecuencia y factores de riesgo de la diabetes mellitus postrasplante renal. Rev Cubana Med. 2002;41(4).

11. Borroto Díaz G, Guerra Bustillo G, Guerrero Díaz C, Infante Suárez A, Gonzáles Álvarez MV. Impacto del virus de la hepatitis C en las complicaciones inmediatas y los trastornos metabólicos glucémicos del trasplante renal. Rev Cubana Med. 2008;47(4).

12. Ridruejo E, Cusumano A, Diaz C, Dávalos Michel M, Jost L, Jost HL, et al. Hepatitis C virus infection and outcome of renal transplantation. Transplant Proc. 2007;39(10):3127-30.

13. Decloux D, Kazory A, Simula-Faivre D, Chalopin JM. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant. 2005;5(12):2922-8.

14. Sancho A, Ávila A, Gavela E, Beltrán S, Fernández-Nájera JE, Molina P, et al. Effect of overweight on kidney transplantation outcome. Transplant Proc. 2007;39(7):2202-4.

15. Kovesdy CP, Czira ME, Rudas A, Ujszaszi A, Rosivall L, Novak M, et al. Body Mass Index, waist circumference and mortality in kidney transplant recipients. Am J Transplantation. 2010;10:2644-51.

16. Borroto G, Guerrero C. Pérez P, Lorenzo A. ¿Es la diabetes mellitus postrasplante una complicación genéticamente determinada? Rev Cubana Med. 2006;45(4):56-9.

17. Limmerman T. Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. Diabetes. 1998;38(3):1238.

18. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T. Insulinresistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15(12):3233-9.

19. Vigano M. Calcineurin inhibitors and mechanisms that is responsible for the appearance of post-transplant diabetes mellitus. G Ital Nefrol. 2003;20(S25):S11-4.

20. Borroto G, Barceló M, Guerrero C, Alonso C. Insulinorresistencia en el trasplante renal. Rev Cubana Invest Biomed. 2002;21(4):241-7.